Merck to develop weight loss pill from Chinese drugmaker

Merck in Pact for Chinese Obesity Drug in Nearly $2 Billion Deal
Merck & Co. snagged a potential drug in the burgeoning market for obesity medications in a deal worth as much as $2 billion.
Merck signs deal worth up to $2 billion with China's Hansoh for oral obesity drug
Merck on Wednesday signed a deal worth up to $2 billion with Hansoh Pharma to develop and sell the Chinese biotech's experimental oral obesity drug that works similar to the popular weight-loss treatments Wegovy and Zepbound.
Merck to develop weight loss pill from Chinese drugmaker in up to $2 billion licensing deal
Merck will pay Hansoh $112 million upfront for rights to the drug, with the potential for an additional $1.9 billion in payments and royalties on sales.
Merck, Hansoh Pharma in Obesity Pill License Potentially Worth More Than $2 Billion
Merck & Co. is licensing a potential oral obesity drug from Hansoh Pharma in a deal potentially worth more than $2 billion to the Chinese biopharmaceutical company. Merck on Wednesday said it will make an upfront payment of $112 million to Hansoh in exchange for an exclusive global license to HS-10535,
Merck signs up to $2 billion obesity drug deal with Chinese biotech Hansoh
U.S. drugmaker Merck on Wednesday signed a deal worth up to $2 billion with Hansoh Pharmaceuticals to develop and commercialize the Chinese biotech's experimental obesity drug. Under the deal, Merck will pay $112 million upfront and Hansoh will be eligible to receive up to $1.
Merck enters obesity drug race in pact with Chinese pharma Hansoh
Merck (NYSE:MRK) and Chinese biopharmaceutical company Hansoh Pharma (OTCPK:HNSPF) announced a global licensing deal on Wednesday to develop HS-10535, an oral GLP-1 receptor agonist targeted at weight loss and other cardio metabolic conditions.

Merck Discontinues Certain Cancer Candidate Trials

Merck targets 2025 RSV season

Strong Fundamentals And Weight Loss Entry Make Merck (MRK) A Buy
Merck has partnered with Hansoh, a Chinese biopharmaceutical company, for a global licensing deal to develop an oral GLP-1 ...
FierceBiotech2h
Merck & Co. boosts GLP-1 portfolio by paying $112M upfront for Hansoh's preclinical drug
Merck & Co. has added a second GLP-1 candidate to its pipeline, paying China’s Hansoh Pharma $112 million upfront for a ...
The Pharma Letter48m
Merck & Co cuts TIGIT and LAG-3 programs
US pharma giant Merck & Co has announced the discontinuation of the clinical development programs for vibostolimab, an ...
Merck & Co. Inc. stock remains steady Tuesday, still outperforms market
Shares of Merck & Co. Inc. MRK were unchanged Tuesday, on what proved to be an all-around dismal trading session for the ...
Merck Enters Into Exclusive Global License Agreement With Hansoh Pharma For HS-10535
(RTTNews) - Merck & Co., Inc. (MRK), Wednesday announced that the company has entered into an exclusive global license deal with China-based Hansoh Pharma to develop, manufacture and commercialize ...
Merck calls quits on two immunotherapies for cancer
The company is scrapping two drugs aimed at targets called TIGIT and LAG-3, both of which were in the middle of Phase 3 ...
Merck Has Become Very Cheap Again
Merck has become inexpensive again and combines a good growth outlook with a nice and growing dividend. Learn why MRK stock ...
JD Health Debuts Merck’s New Diabetes Medication GLUCOPHAGE® XR (Reduce Mass) Online in China
On December 10, JD Health, in collaboration with Merck, a globally renowned biopharmaceutical leader, began offering ...